Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ciclesonide Clear all
Completed Phase 3 Interventional

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NCT00305487
View directory record Official record
Conditions
Hay Fever, Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal spray
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
71
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT01067105
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide HFA 160 μg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
44
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

NCT01451541
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Costa Mesa, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

NCT00458835
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

NCT01248065
View directory record Official record
Conditions
Asthma
Interventions
Vitamin D3, Ciclesonide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

NCT00659048
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

NCT01458275
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
66
States / cities
Little Rock, Arkansas • Baldwin Park, California • Costa Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

NCT00658918
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma

NCT00174746
View directory record Official record
Conditions
Asthma
Interventions
AVE2635A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

NCT00174720
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

NCT01550471
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 15 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

NCT04377711
View directory record Official record
Conditions
COVID-19
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

NCT00163488
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Withdrawn Phase 4 Interventional

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

NCT00793858
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
placebo, isotonic ciclesonide, hypotonic ciclesonide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 4 Interventional

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

NCT00806754
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Ciclesonide HFA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 17, 2026, 3:57 AM EDT
Recruiting Phase 1 Interventional

Inhaled Ciclesonide Study in Preterm Infants

NCT06589245
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Alvesco Inhalant Product
Drug
Lead sponsor
Venkatesh Sampath
Other
Eligibility
8 Days to 35 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 3:57 AM EDT